Skip to main content
Cellular and Molecular Life Sciences: CMLS logoLink to Cellular and Molecular Life Sciences: CMLS
. 2009 Apr 7;66(10):1766–1781. doi: 10.1007/s00018-009-9169-4

PPAR γ partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK

J Kim 1, D C Han 1, J M Kim 1, S Y Lee 1, S J Kim 1, J R Woo 1, J W Lee 1, S-K Jung 1, K S Yoon 1, H G Cheon 2, S S Kim 2, S H Hong 3, B-M Kwon 1,
PMCID: PMC11115545  PMID: 19347570

Abstract.

Indenone KR-62776 acts as an agonist of PPARγ without inducing obesity in animal models and cells. X-ray crystallography reveals that the indenone occupies the binding pocket in a different manner than rosiglitazone. 2-Dimensional gel-electrophoresis showed that the expression of 42 proteins was altered more than 2.0-fold between KR-62776- or rosiglitazone-treated adipocyte cells and control cells. Rosiglitazone down-regulated the expression of ERK1/2 and suppressed the phosphorylation of ERK1/2 in these cells. However, the expression of ERK1/2 was up-regulated in KR-62776-treated cells. Phosphorylated ERK1/2, activated by indenone, affects the localization of PPARγ, suggesting a mechanism for indenone-inhibition of adipogenesis in 3T3-L1 preadipocyte cells. The preadipocyte cells are treated with ERK1/2 inhibitor PD98059, a large amount of the cells are converted to adipocyte cells. These results support the conclusion that the localization of PPARγ is one of the key factors explaining the biological responses of the ligands.

Keywords. Peroxisome proliferators-activated receptor γ, rosiglitazone, adipocyte, lipolysis, ERK, indenone

Footnotes

Received 04 March 2009; received after revision 13 March 2009; accepted 17 March 2009


Articles from Cellular and Molecular Life Sciences: CMLS are provided here courtesy of Springer

RESOURCES